Active Filter(s):
Details:
Recent endorsement of Evrenzo (roxadustat) by the National Institute for Health and Care Excellence (NICE) could be a catalyst for further use as alternative to erythropoietin stimulating agents (ESAs).
Lead Product(s): Roxadustat
Therapeutic Area: Hematology Product Name: Evrenzo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022